Elena V. Mironova

Elena V. Mironova

Auto-generated profile, based on publicly available information

Elena V. Mironova

Central Clinical Hospital “RZD-Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2009 in Neuroscience and Behavioral Physiology
Verified
Journal Article
Closed access
PDF file
AEA. A. Evstratova
A. A. Evstratova
EME. V. Mironova
E. V. Mironova
EDE. A. Dvoretskova
E. A. Dvoretskova
Sergei M AntonovSergei M Antonov
Sergei M Antonov

19 June 2009 in Doklady Biological Sciences
Verified
Journal Article
Closed access
PDF file
Sergei M AntonovSergei M Antonov
Sergei M Antonov
IKIgor Krivoi
Igor Krivoi
TDT. M. Drabkina
T. M. Drabkina
EME. V. Mironova
E. V. Mironova
AEA. A. Evstratova
A. A. Evstratova

26 September 2023 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
DSDmitry Sychev
Dmitry Sychev
TOT. M. Ostroumova
T. M. Ostroumova
OOO. D. Ostroumova
O. D. Ostroumova
AKA. I. Kochetkov
A. I. Kochetkov
SBS. V. Batyukina
S. V. Batyukina
EME. V. Mironova
E. V. Mironova
Scientific relevance. Being the main class of medicinal products for dyslipidaemia treatment, statins are widely used in clinical practice in various patient populations. However, statins can cause statin-associated muscle symptoms (SAMS), which are the most frequent and, in some cases, even life-threatening adverse reactions associated with these medicinal products.Aim.The study aimed to perform a systematic review of the epidemiology, classification, and physiological pathogenesis of SAMS, risk factors for this complication, and clinical guidelines for primary care physicians regarding the identification and treatment of patients with SAMS.Discussion.SAMS is an umbrella term that covers various forms of myopathies associated with satin therapy. According to the published literature, the prevalence of SAMS varies considerably and may depend on the study design, inclusion criteria, and the medicinal product used. SAMS has multiple putative pathogenic pathways that include genetically determined processes, abnormalities in mitochondrial function, defects in intracellular signalling and metabolic pathways, and immune-mediated reactions. The main known risk factors for developing SAMS include high-dose statins, drug–drug interactions, genetic polymorphisms, female sex, older age, Asian race, history of kidney, liver, and muscle disease, and strenuous physical activity. Given the lack of universally recognised algorithms for diagnosing SAMS, clinicians should consider the clinical presentation and the temporal relationship between statin therapy and symptoms. Other factors to consider include changes in muscle-specific enzyme levels and, in some cases, the results of blood tests for antibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.Conclusions.To ensure the safety of statin therapy, it is essential to raise clinicians’ awareness of the risk factors for SAMS, indicative clinical and laboratory findings, and the need for dynamic patient monitoring, including the involvement of clinical pharmacologists.

1 January 2021 in Siberian Medical Review
Verified
Journal Article
Closed access
RERussian Medical Academy Of Continuing Professional Education
Russian Medical Academy Of Continuing Professional Education
JEJebzeeva E.YU
Jebzeeva E.YU
EME.V. Mironova
E.V. Mironova
RMRussian Railways Medicine
Russian Railways Medicine
IKI.F. Krotkova
I.F. Krotkova
OOO.D. Ostroumova
O.D. Ostroumova
Th e most common clinical manifestation of new coronavirus infection is bilateral pneumonia. At the same time, COVID-19 has a wide range of cardiovascular complications, with the development of acute heart failure, arrhythmias, acute coronary syndrome, and myocarditis. Myocardial injury is relatively common in COVID-19, accounting 7-23 % of cases. Th e presented clinical case describes a 56-year-old patient with a confi rmed coronavirus infection. Th e peculiarity of this clinical case is that it is the first report on COVID-19 with systemic manifestations: lungs, heart, kidneys and skin lesions. It should be noted that despite viral pneumonia typical for COVID-19, clinical picture and severity of the patient’s condition were determined by the developed myocardial injury. Th e presented clinical case is specifi c due to skin lesions

18 January 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EEE. Yu. Ebzeeva
E. Yu. Ebzeeva
OOO. D. Ostroumova
O. D. Ostroumova
EME. V. Mironova
E. V. Mironova
NDN. M. Doldo
N. M. Doldo
In the modern world, stress occupies a leading place among significant problems for humanity, being an etiological factor of about 80% of diseases. Social, physical and psychological factors can act as stressors that influence and determine the non-specific response of the body. In most cases, the nonspecific stress-induced reaction of the body is manifested by the picture of psychovegetative syndrome, an important component of which is the activation of the sympathetic nervous system. In a prolonged stress situation, psychovegetative syndrome can be a manifestation of stress-induced anxiety. Anxiety is detected in more than 25% of patients with a general somatic profile. Stress-induced reactions and anxiety can subsequently contribute to the development of psychogenic somatic pathology, including the cardiovascular pathology. Acute or chronic stress situation increases the risks of developing arterial hypertension, coronary heart disease, heart rhythm disorders. In the presence of background cardiac pathology, stress-induced reactions contribute to the deterioration of its course and reduce the effectiveness of treatment. The above indicates the need for a comprehensive assessment of the condition of patients with a general somatic profile. The active use in practical medicine of psychometric and psychodiagnostic scales for anxiety and depression is shown to assess the mental status of patients. When detecting stress-induced reactions or comorbid psychopathology, inclusion of psychotropic drugs, including antipsychotics (alimemazine), is indicated in the complex therapy. Timely administration of alimemazine in patients with a general somatic profile stops psychovegetative manifestations, has positive somatotropic effects due to the multimodal mechanism of action of the drug. In this clinical case, the use of alimemazine in a patient with hypertension, rhythm disorders and comorbid anxiety is presented.

1 January 2021 in Consilium Medicum
Verified
Journal Article
Open access
MEMoscow Russian Medical Academy Of Continuous Professional Education
Moscow Russian Medical Academy Of Continuous Professional Education
OOOlga D. Ostroumova
Olga D. Ostroumova
VBVasiliy N. Butorov
Vasiliy N. Butorov
EMElena V. Mironova
Elena V. Mironova
NDNikolai M. Doldo
Nikolai M. Doldo
In 2021, the world cardiology community celebrates the anniversary of one of the greatest research in clinical medicine – the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study. The study showed that in patients with atrial fibrillation, the use of apixaban was more effective than the use of warfarin in the prevention of stroke or systemic embolism, was accompanied by a lower frequency of bleeding and was associated with lower mortality from all causes. To date, 77 subanalyses of this ambitious study have been published, a brief overview of which is given in the article. As shown by the post-hoc analysis of the ARISTOTLE study, apixaban was equally effective and safe both in patients without comorbidities and in polymorbid patients. The efficacy and safety of apixaban has been demonstrated in atrial fibrillation and in the presence of comorbidities, including diabetes mellitus, chronic kidney disease, obesity, and coronary heart disease. A number of subanalyses of the ARISTOTLE study are devoted to the prognostic assessment of biomarkers such as cardiac troponins, growth differentiation factor-15, pro-B-type N-terminal natriuretic peptide, D-dimer, asymmetric and symmetric dimethylarginine, interleukin-6, C-reactive protein. Based on the study of biomarkers, new, more informative scales for assessing the risk of stroke, death and bleeding were created: the ABC-stroke scale, the ABC-lethal outcome scale and the ABC-bleeding scale. The data of the corresponding sub-analyzes confirmed the greater efficacy and/or safety of apixaban treatment compared with warfarin, regardless of the level of various biomarkers in blood plasma and the degree of risk of stroke, death and bleeding, assessed using both traditional and new scales.